David Kirn is President and Chief Executive Officer of 4D Molecular Therapeutics, Inc. (FDMT). The company reported total compensation of $2,051,343 for fiscal year 2025.
| Salary | $667,252 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $822,750 |
| Non-equity incentive plan | $560,597 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $744 |
| Total | $2,051,343 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure 4D Molecular Therapeutics, Inc. filed April 28, 2026, accession 0001140361-26-017427.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $667,252 | $0 | $0 | $822,750 | $560,597 | $0 | $744 | $2,051,343 |
| FY2024 | President and Chief Executive Officer | $662,780 | $0 | $0 | $0 | $292,662 | $0 | $53,561 | $1,009,004 |
Totals as disclosed in each year's own compensation disclosure for 4D Molecular Therapeutics, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kristian Humer | Chief Financial Officer | $3,990,903 |
| David Kirn this page | President and Chief Executive Officer | $2,051,343 |
| Fariborz Kamal | Former Chief Operating Officer & President | $1,441,573 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full 4D Molecular Therapeutics, Inc. compensation brief.
David Kirn's compensation sits inside 4D Molecular Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.
The 4D Molecular Therapeutics, Inc. (FDMT) compensation brief